TABLE 1.
Baseline characteristics (n = 46)
| Characteristic | Median (% or IQR) value |
|---|---|
| Participant’s age at 1st visit (yr) | 30.94 (27, 34) |
| No. of women from each visit | |
| Second trimester | 7 (8.1) |
| Third trimester | 41 (47.7) |
| 2–3 wk postpartum | 3 (3.5) |
| 6–12 wk postpartum | 35 (40.7) |
| Race | |
| Hispanic | 18 (39.1) |
| Black | 16 (34.8) |
| White, non-Hispanic | 9 (19.6) |
| Asian/Pacific Islander | 1 (2.2) |
| More than 1 race | 1 (2.2) |
| Unknown | 1 (2.2) |
| Prepregnancy wt (kg) | 76.40 (66.30, 96.88) |
| Wt in the 3rd trimester (kg) | 80.6 (50.8, 121.9) |
| Wt gain in 3rd trimester (kg) | 6.85 (4.15, 11.40) |
| Concomitant medications | |
| Ritonavir boosted protease inhibitor | 39 (84.8) |
| Atazanavir-ritonavir | 24 (52.2) |
| Lopinavir-ritonavir | 12 (26.1) |
| Fosamprenavir-ritonavir | 1 (2.2) |
| Saquinavir-ritonavir | 2 (4.3) |
| Emtricitabine | 33 (71.7) |
| Lamivudine | 10 (21.7) |
| Zidovudine | 7 (15.2) |
| Efavirenz | 3 (8.7) |
| Nevirapine | 4 (6.5) |